Notice: This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends RTRX vs. PBH, RARE, RNA, BHVN, OGN, PTCT, RYTM, AKRO, APLS, and CRNXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), Biohaven (BHVN), Organon & Co. (OGN), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Prestige Consumer Healthcare Ultragenyx Pharmaceutical Avidity Biosciences Biohaven Organon & Co. PTC Therapeutics Rhythm Pharmaceuticals Akero Therapeutics Apellis Pharmaceuticals Crinetics Pharmaceuticals Prestige Consumer Healthcare (NYSE:PBH) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Which has more volatility & risk, PBH or RTRX? Prestige Consumer Healthcare has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do analysts recommend PBH or RTRX? Prestige Consumer Healthcare currently has a consensus target price of $92.60, indicating a potential upside of 9.37%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, research analysts clearly believe Prestige Consumer Healthcare is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prestige Consumer Healthcare 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PBH or RTRX more profitable? Prestige Consumer Healthcare has a net margin of 19.13% compared to Travere Therapeutics' net margin of -49.13%. Prestige Consumer Healthcare's return on equity of 12.36% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prestige Consumer Healthcare19.13% 12.36% 6.39% Travere Therapeutics -49.13%-36.38%-14.90% Does the MarketBeat Community favor PBH or RTRX? Prestige Consumer Healthcare received 75 more outperform votes than Travere Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Travere Therapeutics an outperform vote while only 70.51% of users gave Prestige Consumer Healthcare an outperform vote. CompanyUnderperformOutperformPrestige Consumer HealthcareOutperform Votes49570.51% Underperform Votes20729.49% Travere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Do insiders & institutionals have more ownership in PBH or RTRX? 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor PBH or RTRX? In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for Prestige Consumer Healthcare and 0 mentions for Travere Therapeutics. Prestige Consumer Healthcare's average media sentiment score of 1.21 beat Travere Therapeutics' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media. Company Overall Sentiment Prestige Consumer Healthcare Positive Travere Therapeutics Neutral Which has higher earnings and valuation, PBH or RTRX? Prestige Consumer Healthcare has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrestige Consumer Healthcare$1.13B3.73$209.34M$4.2719.83Travere Therapeutics$175.34M6.40-$146.43M-$3.46-6.35 SummaryPrestige Consumer Healthcare beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$7.05B$5.84B$9.13BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-10.426.1426.7919.19Price / Sales6.40267.62434.5471.84Price / CashN/A65.6738.0134.83Price / Book4.276.707.644.62Net Income-$146.43M$138.98M$3.19B$246.06M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$21.98-6.8%N/A+178.9%$1.12B$175.34M-10.42221Gap DownHigh Trading VolumePBHPrestige Consumer Healthcare4.1553 of 5 stars$87.29+0.3%$92.50+6.0%+21.8%$4.31B$1.13B20.44540Positive NewsRAREUltragenyx Pharmaceutical4.6132 of 5 stars$44.78-1.3%$92.43+106.4%-12.9%$4.14B$522.75M-6.921,276Analyst ForecastRNAAvidity Biosciences1.4415 of 5 stars$34.31-1.7%$65.80+91.8%+114.0%$4.09B$9.56M-11.91190BHVNBiohaven3.3961 of 5 stars$38.25-0.5%$63.00+64.7%-22.0%$3.89BN/A-4.09239Short Interest ↓Positive NewsOGNOrganon & Co.4.9503 of 5 stars$15.04+2.8%$21.33+41.9%-16.6%$3.87B$6.26B2.9810,000PTCTPTC Therapeutics3.5944 of 5 stars$49.82+0.7%$57.85+16.1%+94.7%$3.84B$900.66M-8.391,410Analyst ForecastNews CoverageRYTMRhythm Pharmaceuticals4.0683 of 5 stars$58.47-1.2%$68.09+16.5%+27.3%$3.64B$112.53M-13.50140Analyst ForecastInsider TradeNews CoverageAKROAkero Therapeutics4.388 of 5 stars$51.15-5.6%$75.86+48.3%+114.1%$3.57BN/A-13.6430Insider TradeAPLSApellis Pharmaceuticals4.2176 of 5 stars$28.68-2.4%$46.71+62.9%-59.3%$3.57B$396.59M-14.13770Short Interest ↓CRNXCrinetics Pharmaceuticals4.103 of 5 stars$36.53-1.2%$72.64+98.8%+2.1%$3.39B$4.01M-9.79210 Related Companies and Tools Related Companies Prestige Consumer Healthcare Alternatives Ultragenyx Pharmaceutical Alternatives Avidity Biosciences Alternatives Biohaven Alternatives Organon & Co. Alternatives PTC Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Akero Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Crinetics Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTRX) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
